0001933414-24-000035.txt : 20240712 0001933414-24-000035.hdr.sgml : 20240712 20240712163906 ACCESSION NUMBER: 0001933414-24-000035 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240711 FILED AS OF DATE: 20240712 DATE AS OF CHANGE: 20240712 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rodman David Malcom CENTRAL INDEX KEY: 0001672659 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41614 FILM NUMBER: 241114964 MAIL ADDRESS: STREET 1: 3122 STERLING CIRCLE STREET 2: SUITE 200 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mineralys Therapeutics, Inc. CENTRAL INDEX KEY: 0001933414 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: (888) 378-6240 MAIL ADDRESS: STREET 1: 150 N. RADNOR CHESTER ROAD STREET 2: SUITE F200 CITY: RADNOR STATE: PA ZIP: 19087 4 1 wk-form4_1720816738.xml FORM 4 X0508 4 2024-07-11 0 0001933414 Mineralys Therapeutics, Inc. MLYS 0001672659 Rodman David Malcom 150 N. RADNOR CHESTER ROAD, SUITE F200 RADNOR PA 19087 0 1 0 0 Chief Medical Officer 0 Common Stock 2024-07-11 4 M 0 5017 0.54 A 96524 D Common Stock 2024-07-12 4 M 0 6349 1.08 A 102873 D Stock Option 0.54 2024-07-11 4 M 0 5017 0 D 2031-03-11 Common Stock 5017 30104 D Stock Option 1.08 2024-07-12 4 M 0 6349 0 D 2032-07-11 Common Stock 6349 184008 D This balance includes 1,778 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. /s/ Adam Levy, Attorney-in-fact 2024-07-12